Results 71 to 80 of about 438,171 (330)

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

Journal for ImmunoTherapy of Cancer, 2018
Background Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes.
Jay Friedman, Megan Morisada, Lillian Sun, Ellen C. Moore, Michelle Padget, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro, Clint T. Allen   +8 more
doaj   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Identification of a novel immune-related gene prognostic index in pancreatic adenocarcinoma and its implication on tumor immunology [PDF]

, 2022
Shujing Zhou, Xufeng Huang, Szöllősi Attila Gábor, Yi Che Chang Chien   +3 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

T-cell repertoire diversity: friend or foe for protective antitumor response?

Journal of Experimental & Clinical Cancer Research, 2022
Profiling the T-Cell Receptor (TCR) repertoire is establishing as a potent approach to investigate autologous and treatment-induced antitumor immune response. Technical and computational breakthroughs, including high throughput next-generation sequencing
Nicla Porciello, Ornella Franzese, Lorenzo D’Ambrosio, Belinda Palermo, Paola Nisticò   +4 more
doaj   +1 more source

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma [PDF]

, 2016
Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME).
Alvarez, Hector A., Bailey, Peter, Biankin, Andrew V., Chang, David K., Chattopadhyay, Chandrani, Ekmekcioglu, Suhendan, Forget, Marie-Andrée, Grimm, Elizabeth A., Haymaker, Cara, Hwu, Patrick, Kim, Sun-Hee, Maitra, Anirban, Roszik, Jason, San Lucas, Francis A.   +13 more
core   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Exploring the cancerous nexus: the pivotal and diverse roles of USP39 in cancer development

Discover Oncology
The ubiquitin–proteasome system enables post-transcriptional protein modification and is a major pathway for the degradation of most of them in eukaryotic cells.
Yujing Chen, Jingyi Zhang, Jinfeng Yang, Jiawei Zhao, Xiaotong Guo, Juzheng Zhang, Jinfeng Gan, Weijia Zhao, Siqi Chen, Xinwen Zhang, Yi Lin, Jiamin Jin   +11 more
doaj   +1 more source